Phase II study of erlotinib as first line chemotherapy in patients with lung adenocarcinoma with brain metastasis and EGFR mutations.
Phase of Trial: Phase II
Latest Information Update: 25 May 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Brain metastases; Lung cancer
- Focus Therapeutic Use
- 27 Mar 2014 New trial record